US 12,473,554 B2
MRNA treatment nanoparticles
Samuel Deutsch, Walnut Creek, CA (US); Daniel Frimannsson, Alameda, CA (US); Nicole Fay, Alameda, CA (US); Colin McKinlay, Fremont, CA (US); and Ole Haabeth, Emeryville, CA (US)
Assigned to Nutcracker Therapeutics, Inc., Emeryville, CA (US)
Filed by Nutcracker Therapeutics, Inc., Emeryville, CA (US)
Filed on Nov. 27, 2023, as Appl. No. 18/520,449.
Application 18/520,449 is a continuation of application No. 18/048,390, filed on Oct. 20, 2022, granted, now 11,879,126.
Application 18/048,390 is a continuation of application No. PCT/US2021/028312, filed on Apr. 21, 2021.
Claims priority of provisional application 63/014,074, filed on Apr. 22, 2020.
Prior Publication US 2024/0158802 A1, May 16, 2024
Int. Cl. C12N 15/117 (2010.01); A61K 9/14 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC C12N 15/117 (2013.01) [A61K 9/145 (2013.01); A61K 39/12 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/55522 (2013.01); A61K 2039/55538 (2013.01); A61K 2039/892 (2018.08)] 12 Claims
 
1. A method comprising administering a therapeutic mRNA composition to a subject in need thereof, wherein the therapeutic mRNA composition comprises:
a first mRNA scaffold comprising a first mRNA coding region encoding HPV16 E6 E7;
a second mRNA scaffold comprising a second mRNA coding region encoding interleukin-12, wherein the second mRNA coding region has a nucleic acid sequence identical to SEQ ID NO:5; and
a third mRNA scaffold comprising a third mRNA coding region encoding tumor necrosis factor superfamily member 14 (TNFSF14) wherein the third mRNA coding region has a nucleic acid sequence identical to SEQ ID NO:11, and
wherein the first mRNA scaffold, the second mRNA scaffold and, the third mRNA scaffold are encapsulated in a delivery vehicle, wherein the delivery vehicle is selected from the group consisting of lipid nanoparticles, polymer-based nanoparticles, cationic lipids, ionizable lipids, amino-lipidated peptoids, amphipathic molecules/nanoparticles, and tertiary amino lipidated cationic peptoids.